Karl Krupp, MSc, PhD is an Assistant Professor in Division of Public Health Practice & Translational Research in the Mel & Enid Zuckerman College of Public Health at the University of Arizona. He has been involved in public health interventions and research among at-risk disadvantaged communities in the U.S. and India since 2002. His earliest work focused on childhood asthma among African Americans in San Francisco public housing. For the last 15 years he has been working in India on the social determinants of health and noncommunicable diseases. His research on HIV prevention, maternal health, primary and secondary prevention of cervical cancer, vaccine hesitancy, and cardiovascular disease has been documented in more than 80 peer-reviewed publications in MMWR Morb Mortal Wkly, AIDS, BMJ, Vaccine, International Journal of Cardiology, Journal of Medical Microbiology, BMC Infectious Disease, Journal of Adolescent Health, Preventive Medicine, and many others. Dr Krupp co-founded Public Health Research Institute of India (PHRII), a community-based organization in Mysore, India, and has served as Program Director (Salary Donated) since 2006. PHRII is recognized as a Scientific and Industrial Research Organization by the Government of India and is now an NIH training and research site that has hosted more than 50 US students and researchers from across the country. Dr. Krupp holds a bachelor’s degree in Communications from the University of Minnesota, a master’s degree in Public Health from London School of Hygiene and Tropical Medicine at London University, and a PhD in Public Health from Florida International University in Miami. For his dissertation research that was entitled “Prevalence and Correlates of Coronary Heart Disease in Slum-Dwelling South Indian Women”, he was funded by the NHLBI and Fogarty International Center as a Global Health Equity Scholar. Since the start of the COVID-19 pandemic in January 2020, Dr Krupp has been working on the psychological antecedents of COVID-19 vaccine intentions among adults in Arizona, and validation of a microRNA panel for detection of Cervical Cancer funded by the Office for Research, Innovation and Impact at the University of Arizona.

Cancer Focus